biodegrad
nanoparticlebas
vaccin
develop
research
unexplor
larg
anim
human
studi
illustr
efficaci
nanoparticleentrap
uvkil
viru
vaccin
econom
import
respiratori
viral
diseas
pig
call
porcin
reproduct
respiratori
syndrom
viru
prrsv
entrap
plga
poli
lactidecoglycolid
nanoparticl
kill
prrsv
antigen
nanokag
detect
phagocytosi
pig
alveolar
macrophag
singl
dose
nanokag
vaccin
administ
intranas
pig
upregul
innat
prrsv
specif
adapt
respons
virul
heterolog
prrsv
challeng
studi
nanokag
vaccin
significantli
reduc
lung
patholog
viremia
viral
load
lung
immunolog
enhanc
innat
adapt
immun
cell
popul
associ
cytokin
decreas
secret
immunosuppress
mediat
observ
mucos
site
blood
summari
demonstr
benefit
intranas
deliveri
nanoparticlebas
viral
vaccin
elicit
crossprotect
immun
respons
pig
potenti
larg
anim
model
microencapsul
vaccin
agent
drug
biodegrad
polym
deliveri
human
innov
approach
creat
robust
medic
vaccin
st
centuri
biocompat
biodegrad
polym
plga
poli
lactidecoglycolid
us
fda
approv
materi
develop
nanoparticlebas
control
releas
deliveri
system
plga
slowli
degrad
releas
vaccin
longperiod
time
thu
avoid
need
booster
dose
particul
natur
nanoparticlemedi
deliveri
promot
uptak
ag
profession
antigen
present
cell
apc
nanoparticl
deliveri
vehicl
vaccin
drug
extens
evalu
mous
model
howev
limit
translat
novel
rodent
find
improv
human
food
anim
health
therefor
pig
may
serv
use
larg
anim
model
research
moreov
due
physiolog
anatom
immunolog
similar
human
pig
alreadi
use
anim
model
system
studi
viral
diseas
although
current
studi
focus
respiratori
pathogen
infect
pig
vaccin
evalu
strategi
may
help
consid
pig
model
system
among
swine
diseas
porcin
reproduct
respiratori
syndrom
prr
highli
devast
caus
estim
econom
loss
million
annual
us
translat
million
loss
per
day
annual
prrsv
infect
pig
age
caus
highli
mutat
posit
sens
singl
strand
rna
viru
belong
famili
arterivirida
prr
grow
pig
caus
anorexia
fever
respiratori
distress
enhanc
suscept
secondari
microbi
infect
pregnant
sow
character
reproduct
dysfunct
abort
primari
prrsv
permiss
cell
alveolar
macrophag
mw
prrsv
rapidli
modul
host
innat
immun
respons
dampen
nk
cell
cytotox
reduc
ifna
product
upregul
immunosuppress
mediat
earli
two
day
postinfect
lead
poor
adapt
immun
respons
delayedweak
viru
neutral
antibodi
respons
result
prrsv
persist
nevertheless
due
high
degre
constant
genet
antigen
variat
control
prr
remain
challeng
swine
industri
worldwid
optim
mucos
immun
induc
protect
immun
respons
mucos
system
site
compar
system
immun
gener
protect
iga
respons
essenti
reduc
andor
prevent
entri
pathogen
whose
principl
port
entri
mucos
site
mucos
immun
induc
effect
immun
respons
local
distant
effector
site
particul
antigen
deliveri
system
facilit
passag
ag
mucos
barrier
lead
stimul
underli
mucos
immun
cell
biodegrad
microspher
made
chitosan
plga
liposom
use
deliv
candid
vaccin
mucos
site
studi
use
nanoparticleentrap
kill
influenza
viru
vaccin
administ
adjuv
intranas
mice
rabbit
pig
elicit
protect
immun
respons
better
immun
induc
pig
intranas
compar
intramuscular
rout
vaccin
singl
intranas
deliveri
plga
nanoparticleentrap
schistosoma
mansoni
ag
mice
elicit
protect
neutral
antibodi
respons
lung
blood
sinc
late
modifi
live
prrsv
prrsmlv
kill
viru
vaccin
use
control
prr
neither
protect
pig
complet
heterolog
field
virus
like
field
viru
prrsmlv
also
induc
immunosuppress
moreov
report
revers
vaccin
viru
virul
lead
sever
diseas
outbreak
although
avail
kill
prrsv
vaccin
safe
poorli
immunogen
thu
control
prr
outbreak
innov
vaccin
strategi
requir
current
studi
kill
prrsv
ag
encapsul
plga
nanoparticl
character
candid
vaccin
vitro
preand
postchalleng
studi
pig
variou
immun
correl
protect
analyz
mucos
system
site
show
evid
crossprotect
immun
prepar
vaccin
antigen
plga
nanoparticlekil
prrsv
vaccin
nanokag
cellmonolay
infect
prrsv
strain
moi
multipl
infect
harvest
infect
cell
cultur
fluid
clarifi
subject
ultracentrifug
sucros
overlay
hr
semipurifi
viral
pellet
suspend
pb
titrat
inactiv
uv
irradi
nm
uvirradi
el
seri
uv
lamp
uvp
llc
ca
hz
amp
hr
sonic
protein
content
estim
use
bca
kit
biorad
ca
viral
inactiv
confirm
cell
cultur
immunofluoresc
assay
cell
viral
pellet
aliquot
store
control
antigen
prepar
similarli
use
uninfect
cell
steril
precaut
follow
throughout
antigen
prepar
process
procedur
avoid
bacteri
contamin
nanoparticl
prepar
use
standard
doubl
emuls
solvent
evapor
techniqu
briefli
plga
mg
dissolv
mg
kill
protein
homogen
rpm
second
ad
aqueou
solut
polyvinyl
alcohol
homogen
final
prepar
stir
overnight
wash
nanoparticl
freezedri
store
amount
entrap
prrsv
protein
nanoparticl
determin
describ
previous
size
shape
nanoparticl
determin
scan
electron
microscopi
hitachi
bronchoalveolar
lavag
fluid
bal
collect
three
week
old
healthi
spf
pig
process
isol
mononuclear
cell
balmnc
balmnc
cell
per
ml
plate
well
plate
contain
polyllysin
coat
cover
slip
hr
nonadher
cell
aspir
adher
cell
treat
freezedri
nanokag
contain
differ
concentr
prrsv
protein
suspend
dmem
contain
fb
cell
uninfect
infect
prrsv
strain
moi
hr
includ
control
cell
fix
paraformaldehyd
min
permeabil
triton
block
pb
contain
bsa
triton
hr
room
temperatur
rt
subsequ
treat
antiprrsv
nucleocapsid
specif
mab
rural
technolog
inc
earli
endosom
specif
goat
polyclon
antiearli
endosom
antigen
igg
santa
cruz
biotechnolog
santa
cruz
ca
dilut
dilut
buffer
pb
contain
bsa
triton
hr
rt
follow
treatment
goat
antimous
igg
alexa
donkey
antigoat
alexa
flour
invitrogen
incub
hr
rt
cell
wash
treatment
step
treat
mount
medium
contain
dabco
sigma
stain
coverslip
mount
clean
glass
slide
use
transpar
nail
polish
view
leica
confoc
microscop
acquir
imag
analyz
use
leica
confoc
softwar
vitro
uptak
nanokag
pig
mw
determin
express
balmnc
cell
per
ml
seed
plate
untreat
treat
kag
nanokag
mgml
prrsv
protein
incub
hr
cell
uninfect
infect
prrsv
strain
moi
hr
serv
control
cell
treat
antiprrsv
n
mab
follow
goat
antimous
igg
alexa
wash
fix
analysi
assess
express
profession
antigen
present
cell
apc
balmnc
treat
hr
wash
stain
use
biotinyl
human
immunoglobulin
fusion
protein
ancel
mn
peconjug
southern
biotech
follow
streptavidin
cell
fix
analyz
use
fac
aria
ii
bd
bioscienc
flow
cytomet
convent
larg
whiteduroc
crossbr
wean
specificpathogenfre
spf
pig
three
differ
litter
wk
age
confirm
seroneg
prrsv
porcin
respiratori
corona
viru
transmiss
gastroenter
viru
porcin
circo
viru
antibodi
prechalleng
studi
pig
n
group
randomli
three
group
n
per
group
group
iunvaccin
mock
pig
inocul
dmem
pb
group
ii
inocul
kag
group
iii
inocul
nanokag
vaccin
nanokag
kag
dose
one
mg
crude
viral
prepar
contain
tcid
inactiv
viru
vaccin
inocul
intranas
pig
euthan
postimmun
day
pid
evalu
innat
viru
specif
adapt
immun
respons
postchalleng
studi
pig
n
divid
randomli
four
group
n
per
group
group
mock
pig
group
ii
inocul
normal
salin
group
iii
inocul
kag
group
iv
inocul
nanokag
vaccin
dose
amount
ag
describ
group
ii
iii
iv
challeng
prrsv
tcid
ml
ml
per
pig
pid
euthan
day
postchalleng
dpc
pc
inocul
perform
intranas
rout
dose
nanokag
mg
per
pig
chosen
base
result
dosedepend
respons
studi
perform
earlier
pig
mockinocul
pig
euthan
separ
sacrif
viru
challeng
anim
pig
receiv
food
water
ad
libitum
maintain
supervis
veterinarian
pig
maintain
sampl
collect
euthan
per
standard
procedur
necessari
effort
minim
suffer
anim
anim
use
protocol
approv
committe
ethic
anim
experi
ohio
state
univers
studi
carri
strict
accord
recommend
public
health
servic
polici
unit
state
depart
agricultur
regul
nation
research
council
guid
care
use
laboratori
anim
feder
anim
scienc
societi
guid
care
use
agricultur
anim
agricultur
research
teach
relev
institut
state
feder
regul
polici
regard
anim
care
use
ohio
state
univers
protocol
approv
committe
ethic
anim
experi
ohio
state
univers
protocol
number
pig
maintain
sampl
collect
euthan
effort
made
minim
suffer
anim
necropsi
lung
lymph
node
examin
grossli
histolog
macroscop
pulmonari
lesion
given
estim
score
base
percentag
consolid
lesion
individu
lobe
describ
previous
lung
tissu
sampl
collect
caudal
lobe
fix
neutral
buffer
formalin
section
mm
made
stain
hematoxylinandeosin
h
e
describ
previous
frozen
lung
section
immunostain
describ
previous
briefli
section
treat
prrsv
nucleocapsid
protein
specif
mab
isotyp
control
mab
follow
abc
peroxidas
stain
kit
vectastain
elit
vector
lab
label
visual
applic
dab
substrat
vector
laboratori
counterstain
hematoxylin
immunostain
slide
examin
unbias
certifi
veterinari
pathologist
score
presenc
prrsv
ag
prrsv
titer
viru
neutral
antibodi
titer
serum
lung
homogen
analyz
indirect
immunofluoresc
assay
ifa
previous
describ
prrsv
specif
iga
igg
antibodi
serum
lung
lysat
homogen
analyz
elisa
briefli
elisa
plate
coat
pretitr
semipurifi
kill
prrsv
ag
mgml
carbonatebicarbon
buffer
ph
wash
block
tween
pb
serum
lung
lysat
mgml
wv
sampl
ad
incub
hr
rt
bound
viru
specif
isotyp
antibodi
detect
use
antipig
iga
igg
secondari
antibodi
conjug
hrp
kpl
plate
develop
use
chromogen
tmb
read
nm
also
includ
nonprrsv
antigenco
plate
control
od
valu
obtain
experiment
plate
subtract
control
five
million
pig
pbmc
tbln
tracheobronchi
lymph
node
mnc
lung
mnc
subject
ex
vivo
restimul
absenc
presenc
prrsv
ag
mgml
describ
previous
harvest
supernat
analyz
measur
cytokin
cytokin
secret
immun
cell
cultur
absenc
prrsv
ag
subtract
correspond
test
valu
serum
sampl
harvest
cultur
supernat
lung
lysat
analyz
ifnc
proinflammatori
immunosuppress
tgfb
cytokin
elisa
amount
cytokin
present
lung
lysat
normal
picogram
per
gram
lung
tissu
flow
cytometri
analysi
perform
determin
phenotyp
frequenc
differ
immun
cell
multicolor
immunoassay
describ
previous
sinc
mnc
isol
differ
amount
weight
tissu
lung
tbln
assess
absolut
cell
number
studi
determin
rel
frequenc
individu
immun
cell
subset
immunostain
fix
number
mnc
one
million
site
collect
event
acquir
bd
fac
aria
ii
bd
bioscienc
analyz
use
flowjo
softwar
data
express
mean
three
pig
sem
statist
analys
perform
use
one
way
analysi
varianc
anova
follow
posthoc
tukey
test
use
graphpad
instat
softwar
version
establish
differ
among
unvaccin
kag
nanokag
pig
group
postchalleng
trial
kag
nanokag
pig
group
prechalleng
trial
statist
signific
assess
morpholog
sham
prrsv
ag
entrap
plga
nanoparticl
determin
scan
electron
microscopi
reveal
size
particl
nm
figur
averag
protein
content
nanoparticl
coreload
ww
repres
encapsul
effici
upon
redispers
nanokag
pb
prrsv
protein
releas
slowli
first
hr
later
gradual
releas
profil
observ
next
data
shown
uptak
nanokag
apc
studi
use
balmnc
harvest
three
healthi
spf
pig
confoc
imag
alveolar
mw
reveal
preferenti
uptak
nanokag
unentrap
viral
ag
kag
prrsv
infect
cell
serv
posit
control
figur
b
engulf
nanoparticl
deliv
prrsv
ag
earli
endosom
compar
virusinfect
control
figur
c
nanokag
engulf
apc
underw
matur
indic
significantli
increas
express
figur
e
addit
balmnc
treat
nanokag
posit
prrsv
protein
compar
viru
infect
cell
figur
f
ii
iv
contrast
balmnc
treat
kag
posit
viral
protein
figur
f
iii
result
suggest
prrsv
ag
deliv
nanoparticl
phagocytos
apc
releas
protein
found
endosom
prechalleng
studi
intranas
deliveri
nanokag
result
induct
innat
immun
respons
mucos
system
site
indic
signific
increas
frequenc
nk
cell
dc
cd
cell
lung
mnc
figur
ac
cd
cell
dc
pbmc
compar
kag
vaccin
pig
figur
h
immun
cell
involv
adapt
arm
immun
respons
cell
thmemori
cell
increas
significantli
lung
mnc
nanokag
compar
kag
vaccin
pig
figur
e
lung
mnc
pbmc
nanokag
immun
pig
secret
significantli
reduc
level
cytokin
higher
amount
recal
respons
figur
f
g
j
addit
innat
cytokin
ifna
secret
significantli
higher
level
pig
vaccin
nanokag
compar
control
group
figur
k
postchalleng
studi
nanokag
vaccin
challeng
pig
clinic
healthi
fever
respiratori
distress
contrast
kag
unvaccin
challeng
pig
irregular
fever
reduc
feed
intak
first
twoweek
postchalleng
microscop
examin
h
e
stain
lung
section
unvaccin
kag
vaccin
challeng
pig
reveal
sever
pneumon
lesion
massiv
infiltr
mononuclear
cell
larg
consolid
area
contrast
significantli
reduc
lung
lesion
observ
nanokag
vaccin
viru
challeng
pig
figur
significantli
reduc
gross
lung
lesion
score
nanokag
immun
group
compar
two
viru
challeng
group
observ
figur
c
immunohistochemistri
analysi
reveal
abund
prrsv
antigen
posit
cell
lung
section
unvaccin
kag
vaccin
challeng
pig
compar
nanokag
receiv
pig
figur
b
prrsv
titer
serum
sampl
indic
reduc
viral
load
greater
onelog
pc
complet
viral
clearanc
pc
nanokag
vaccin
compar
kag
vaccin
unvaccin
pig
figur
e
similarli
prrsv
load
lung
also
reduc
although
signific
nanokag
compar
kag
immun
viru
challeng
pig
figur
f
also
prrsv
titer
tcid
ml
serum
lung
homogen
show
lung
homogen
nanokag
immun
pig
contain
significantli
higher
level
viru
specif
iga
igg
antibodi
compar
unvaccin
kag
vaccin
challeng
pig
figur
b
serum
sampl
nanokag
vaccin
pig
increas
iga
antibodi
level
pc
sampl
collect
day
viral
challeng
inocul
challeng
viru
signific
increas
pc
compar
either
unvaccin
kag
vaccin
challeng
pig
detect
figur
prrsv
specif
igg
antibodi
level
serum
figur
e
iga
igg
level
nasal
swab
figur
g
h
significantli
higher
nanokag
vaccin
compar
unvaccin
kag
immun
pig
dpc
significantli
increas
prrsv
specif
neutral
antibodi
vn
titer
serum
kag
nanokag
vaccin
receiv
pig
group
observ
pc
still
remain
high
although
signific
nanokag
group
pc
lung
similar
trend
increas
signific
titer
neutral
antibodi
nanokag
immun
pig
seen
figur
c
f
nanokag
vaccin
receiv
viru
challeng
pig
significantli
increas
innat
ifna
product
lung
figur
kag
vaccin
unvaccin
pig
fourfold
reduct
nk
cell
frequenc
compar
mock
pig
observ
contrast
nanokag
vaccin
pig
nk
cell
frequenc
significantli
higher
kag
unvaccin
viru
challeng
pig
figur
b
lung
nk
cellcytotox
function
unvaccin
kag
vaccin
viru
challeng
pig
complet
suppress
howev
nanokag
receiv
pig
partial
rescu
figur
c
frequenc
cd
cell
cell
lung
nanokag
vaccin
anim
significantli
increas
compar
kag
unvaccin
viru
challeng
pig
figur
e
f
peripher
blood
nanokag
immun
pig
significantli
increas
frequenc
dc
tbln
significantli
increas
frequenc
dc
cd
cell
observ
tabl
pig
vaccin
nanokag
significantli
reduc
tregulatori
cell
treg
popul
lung
compar
unvaccin
kag
receiv
pig
figur
immuno
suppress
cytokin
tgfb
respons
lung
significantli
reduc
nanokag
vaccin
pig
also
decreas
secret
detect
lung
mnc
restimul
kill
ag
figur
b
c
e
f
contrast
significantli
increas
ifnc
lung
homogen
secret
antigen
restimul
lung
mnc
detect
nanokag
vaccin
pig
figur
g
addit
pbmc
secret
significantli
reduc
tgfb
compar
kag
vaccin
viru
challeng
pig
figur
h
tblnmnc
increas
seen
compar
viru
challeng
group
figur
l
increas
ifnc
secret
pbmc
tblnmnc
nanokag
vaccin
group
compar
kag
immun
pig
figur
j
level
proinflammatori
cytokin
restimul
respons
significantli
reduc
tblnmnc
nanokag
compar
viru
challeng
pig
figur
k
n
nanoparticl
mediat
vaccin
deliveri
shown
great
promis
mous
model
influenza
parainfluenza
hepat
b
plasmodium
venezuelan
equin
enceph
pathogen
howev
knowledg
relat
crossprotect
efficaci
vaccin
suitabl
larg
anim
model
limit
studi
reveal
potenc
nanoparticleentrap
prrsv
vaccin
pig
prr
dread
diseas
caus
huge
econom
loss
major
swine
produc
countri
world
nanokag
vaccin
upregul
frequenc
major
innat
immun
player
nk
cell
cd
cell
dc
also
enhanc
secret
antivir
cytokin
ifna
ifnc
otherwis
suppress
prrsv
suggest
nanokag
vaccin
virul
heterolog
prr
challeng
pig
effector
play
pivot
role
viral
clearanc
contrast
increas
viral
load
lung
kag
vaccin
pig
perhap
due
antibodymedi
enhanc
uptak
lung
determin
immunofluoresc
assay
bar
repres
averag
valu
three
pig
sem
asterisk
repres
statist
signific
differ
kag
nanokag
receiv
pig
group
q
repres
statist
signific
differ
unvaccin
nanokag
receiv
pig
group
similar
trend
result
obtain
independ
second
trial
perform
use
number
anim
prrsv
alveolar
mw
addit
increas
immunosuppress
respons
particul
ag
inher
affin
mucos
cell
apc
phagocytos
passiv
apc
nanoparticl
protect
entrap
protein
proteasemedi
degrad
mucos
surfac
also
aid
slow
sustain
releas
vaccin
plga
nanoparticl
induc
activ
matur
human
dc
upregul
express
costimulatori
mhc
class
ii
molecul
secret
proinflammatori
cytokin
enhanc
apc
allostimulatori
properti
consist
inher
adjuv
properti
plga
pig
apc
treat
plga
nanoparticl
vaccin
nanokag
increas
express
costimulatori
molecul
studi
includ
pig
group
empti
pgla
nanoparticl
primari
goal
augment
kill
prrsv
vaccin
induc
antiprrsv
crossprotect
immun
help
plga
wellknown
adjuv
deliveri
system
vaccin
thu
present
inform
much
postvaccin
cell
immun
detect
nanokag
vaccin
pig
due
adjuv
effect
pgla
nanoparticl
alon
consid
futur
investig
howev
rapid
uptak
nanokag
lung
apc
follow
transloc
viral
ag
endosom
compart
observ
suggest
viru
specif
adapt
immun
respons
could
elicit
respiratori
tract
pig
use
plga
nanoparticlebas
kill
prrsv
vaccin
differenti
cell
count
bal
fluid
harvest
healthi
mice
human
pig
indic
greater
cell
alveolar
mw
suggest
intranas
deliv
nanokag
phagocytos
mw
earlier
studi
demonstr
rapid
uptak
chitosan
nanoparticl
apc
follow
gradual
releas
antigen
due
slow
rate
degrad
chitosan
lysozym
result
increas
express
costimulatori
molecul
activ
dc
antigen
present
mhc
class
ii
molecul
prechalleng
studi
nanokag
vaccin
significantli
increas
frequenc
cell
th
memori
cell
concomit
increas
secret
innat
ifna
proinflammatori
ifnc
cytokin
immun
potenti
abil
chitosan
nanoparticl
mediat
action
innat
immun
cell
addit
enhanc
product
ifnc
phagocytosi
polystyren
latex
microspher
mw
activ
signal
transduct
event
innat
immun
cell
activ
apc
present
antigen
mhc
class
ii
molecul
cell
respect
postchalleng
studi
use
virul
heterolog
prrsv
nanokag
induc
superior
innat
immun
respons
observ
studi
shown
immun
potenti
activ
nanoparticl
mice
pig
macaqu
immun
correl
evalu
vaccin
viru
challeng
anim
immunolog
prrsv
modul
innat
immun
function
pig
dampen
ifna
product
nk
cell
frequenc
well
cytotox
lead
weak
delay
adapt
immun
respons
nk
cytotox
function
nanokag
receiv
pig
partial
rescu
signific
suggest
begin
appear
nk
cell
cytotox
function
complet
rescu
frequenc
compar
mock
pig
pig
vaccin
nanokag
viru
induc
immunosuppress
respons
dampen
along
signific
boost
innat
viru
specif
adapt
immun
respons
cd
cell
import
innat
immun
cell
mucos
site
possess
nonmhc
class
cytolyt
activ
pig
possess
rel
larg
popul
cd
cell
compar
speci
secret
ifnc
cd
cell
play
import
role
reduc
vaccinia
viru
load
also
destruct
herp
simplex
type
infect
cell
nanokag
vaccin
pig
increas
popul
cd
cell
addit
nk
cell
cell
increas
secret
ifnc
detect
mucos
system
site
earlier
demonstr
kag
mlvprr
vaccin
viru
challeng
well
unvaccin
prrsv
infect
pig
immunosuppress
respons
mediat
increas
popul
treg
secret
tgfb
reduc
product
ifnc
contrast
nanokag
immun
pig
lung
tbln
blood
significantli
reduc
treg
frequenc
associ
decreas
tgfb
increas
ifnc
secret
compar
unvaccin
kag
vaccin
viru
challeng
pig
observ
prechalleng
studi
twoweek
postvaccin
increas
secret
proinflammatori
cytokin
nanokag
vaccin
pig
appear
involv
initi
adapt
immun
respons
diminish
product
postchalleng
pig
sixweek
postvaccin
associ
reduc
inflammatori
lung
patholog
mucos
immun
elicit
product
iga
antibodi
effector
respons
distant
tissu
iga
antibodi
protect
variou
viral
infect
possess
signific
viru
neutral
activ
mucos
surfac
blood
nanokag
immun
pig
increas
level
prrsv
specif
iga
igg
lung
blood
nasal
wash
observ
although
prrsv
specif
antibodi
significantli
increas
neutral
titer
lung
complet
clearanc
viremia
pc
associ
variou
adapt
immun
correl
wherea
lung
reduc
viral
titer
signific
signific
reduct
prrsv
antigen
immunohistochemistri
reduc
lung
patholog
implic
presenc
activ
antiprrsv
mucos
immun
respons
elicit
nanokag
vaccin
lung
fig
import
find
studi
swine
farmer
research
pig
vaccin
intranas
nanokag
vaccin
complet
clear
prrsv
viremia
virul
heterolog
viru
twoweek
postchalleng
yet
anoth
nanokag
vaccin
studi
inocul
booster
dose
vaccin
coadminist
potent
mucos
adjuv
intranas
show
complet
clearanc
replic
heterolog
prrsv
lung
clearanc
viremia
earlier
current
studi
binjawadagi
et
al
manuscript
submit
conclus
studi
suggest
innov
strategi
intranas
deliveri
prrsv
nanokag
vaccin
potenti
control
prr
outbreak
potenti
reduc
econom
loss
swine
produc
consid
pig
use
larg
anim
model
studi
may
serv
use
impetu
undertak
intranas
plga
nanoparticlebas
vaccin
trial
human
respiratori
viral
infect
bar
repres
averag
valu
three
pig
sem
asterisk
repres
statist
signific
differ
nanokag
kag
receiv
pig
group
q
repres
statist
signific
differ
unvaccin
nanokag
receiv
pig
group
similar
trend
result
obtain
independ
second
trial
perform
use
number
anim
